Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 6/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 3/20 | 0.40 |
| ▸ | CHUK | O15111 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23717048 | 0.84 | CYP11B1 (0.47) | PDE4AIKBKBCHUKLCKROCK1 | |
| SCHEMBL23717043 | 0.81 | ROCK2 (0.39) | PDE4AROCK1PDE4DPDE4BPDE4C | |
| SCHEMBL24984553 | 0.80 | HRH1 (0.53) | HRH1IKBKBCHUKLCKROCK1 | |
| SCHEMBL11951612 | 0.79 | CASR (0.53) | CASR | |
| SCHEMBL24345432 | 0.79 | HTR2C (0.45) | PDE4APDE4DPDE4BPDE4CSLC6A4 | |
| SCHEMBL7227806 | 0.76 | HRH1 (0.76) | HRH1PDE4AIKBKBCHUKLCK | |
| SCHEMBL27425814 | 0.75 | PDE4A (0.46) | PDE4AFFAR1PDE4DPDE4BPDE4C | |
| SCHEMBL27427439 | 0.74 | PDE4A (0.46) | PDE4AFFAR1PDE4DPDE4BPDE4C | |
| SCHEMBL14268228 | 0.74 | ACACB (0.39) | PDE4ASLC6A4HTR2CHTR2B | |
| SCHEMBL16942606 | 0.74 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4CHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | HRH1 17/4885PDE4A 961/4885METAP2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.